R&D Leadership Succession and the Fruits of 10 Years of Innovation

Andy Plump, president of Takeda Pharmaceutical, who has overseen its global R&D for over a decade, has decided to retire in June next year. Dr. Plump, recruited in 2015 after serving at Sanofi, is the key figure who transformed Takeda into a global biopharma. This retirement is being formalized at a time when the permitting achievements of major pipelines have reached their peak, thereby minimizing uncertainty within the organization. Until new leadership is appointed, Plump will continue to lead the organization steadily, ensuring a seamless transition with no gaps in operations.

Success of New Drug Approvals and Overwhelming Late-Stage Pipeline Performance

The background of Plump's retirement lies in the recent string of regulatory approvals for major innovative new drugs. In August 2026, Takeda obtained US FDA and Japanese MHLW approval for Orzeyful (active ingredient: oveporexton), an orexin 2 receptor (OX2R) agonist for Type 1 Narcolepsy (NT1). On the 28th of the same month, Mimrylo (active ingredient: rusfertide), a hepcidin mimetic co-developed with Protagonist, received FDA approval as a treatment for polycythemia vera (PV). Additionally, zasocitinib (TAK-279), a TYK2 inhibitor acquired from Nimbus for $4 billion, is preparing for regulatory filing after demonstrating superior skin improvement rates compared to BMS's Sotyktu in the Phase 3 (LATITUDE) trial for plaque psoriasis.

Defending Against Blockbuster Patent Expirations and Challenges for the Next Successor

The next R&D head will bear the heavy responsibility of establishing new growth engines to fill the revenue gap caused by the loss of exclusivity (LoE) of flagship medicines. Takeda has already experienced revenue hits due to the generic entry of the ADHD treatment Vyvanse in 2023. Furthermore, as the inflammatory bowel disease treatment Entyvio (active ingredient: vedolizumab), which generates $5 billion in annual revenue, faces upcoming biosimilar competition, pipeline succession is urgent. With President Plump placing Orzeyful and Mimrylo on the commercialization track following Rivtenicity, Adzintity, and Iohelia, the next leadership will direct commercial expansion from a relatively solid foothold.

Strategic Resolution of Cell Therapy Failures and Pipeline Reorganization

During Plump's tenure as president, painful strategic revisions followed in the field of cell therapy. Following a significant impairment loss on assets acquired from GammaDelta Therapeutics, Takeda has abruptly withdrawn from the development of its cell therapy platform. Alofisel, a treatment for Crohn's disease fistula acquired through the acquisition of TiGenix, also voluntarily withdrew its European marketing authorization following Phase 3 clinical failure. Amid these trials and errors, the bold disposal of non-performing assets and the restructuring of the portfolio around high-confidence small molecules and peptide mimetics drove Takeda's structural transformation.